戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rd-dose group received an additional placebo suppository.
2 g estrus compared with mice receiving saline suppositories.
3 plicators for insertion of medicated gels or suppositories.
4  women's willingness to try soft-gel vaginal suppositories.
5 ratio to be treated with VagiBIOM or placebo suppositories.
6  (OR, 0.59; 95% CI, 0.34, 0.93) and cream or suppository administrations (OR, 0.57; 95% CI, 0.34, 0.9
7 ERCP to receive either two 50 mg indometacin suppositories and a placebo suppository (standard-dose g
8 les, smokables, drinkables, vaping products, suppositories) and potencies relies on a questionable se
9  miscarriages to receive twice-daily vaginal suppositories containing either 400 mg of micronized pro
10 en were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone o
11 riments, mice were given vaginal agarose gel suppositories containing either 5 mg OVA or saline for 6
12  L microbiome by using, for example, vaginal suppositories containing live lactobacilli, would alter
13 ), were randomly assigned to receive vaginal suppositories containing metronidazole 750 mg plus micon
14 ately after endoscopy, patients were given a suppository containing either 100 mg diclofenac or place
15 tly reduced in mice receiving OVA-containing suppositories during estrus compared with mice receiving
16                              Mice were given suppositories either during the estrous (estrogen domina
17  has recommended the use of artesunate (ATS) suppositories for emergency treatment of patients, howev
18          Finally, the clinical efficacy of a suppository formulation containing both pancreatic pro-e
19 ndard-dose group) or three 50 mg indometacin suppositories (high-dose group).
20 pected severe malaria with rectal artesunate suppositories in remote areas.
21 f rectal indomethacin (n = 223) or a placebo suppository (n = 226) during the procedure.
22 n and patients' compliance, over injectable, suppositories, ocular and nasal.
23 ive 100 mg of rectal indomethacin or a 2.6 g suppository of glycerin immediately after ERCP, without
24 .5 GBq) on day 1 in combination with a NOX66 suppository on days 1-10 of each 6-wk cycle.
25 duct VagiBIOM, a multi-Lactobacillus vaginal suppository, on peri- and premenopausal women with BV in
26 0 mg indometacin suppositories and a placebo suppository (standard-dose group) or three 50 mg indomet
27 feasible and alternate routes such as rectal suppositories, subcutaneous infusions, and orally dissol
28 livery systems (DDS) including creams, gels, suppositories, tablets, rings, and films have been devel
29                                 The VagiBIOM suppository treatment for peri- and premenopausal women
30 ure or anal-canal dressing, and a diclofenac suppository was administered at the end of the procedure
31 oup received an additional 50 mg indometacin suppository, whereas patients in the standard-dose group